Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Published version of a preprint
The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.
Abstract
PURPOSE: To identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the first-in-class, oral CDK4/6 inhibitor PD 0332991 administered once daily for 21 of 28 days (3/1 schedule) in patients with retinoblastoma protein (Rb)-positive advanced solid tumors and to describe pharmacokinetic-pharmacodynamic relationships relative to drug effects. EXPERIMENTAL DESIGN: This open-label phase I study (NCT00141297) enrolled patients who received PD 0332991 orally in six dose-escalation cohorts in a standard 3 + 3 design. RESULTS: Forty-one patients were enrolled. DLTs were observed in five patients (12%) overall; at the 75, 125, and 150 mg once daily dose levels. The MTD and recommended phase II dose of PD 0332991 was 125 mg once daily. Neutropenia was the only dose-limiting effect. After cycle 1, grade 3 neutropenia, anemia, and leukopenia occurred in five (12%), three (7%), and one (2%) patient(s), respectively. The most common non-hematologic adverse events included fatigue, nausea, and diarrhea. Thirty-seven patients were evaluable for tumor response; 10 (27%) had stable disease for ≥4 cycles of whom six derived prolonged benefit (≥10 cycles). PD 0332991 was slowly absorbed (median T(max), 5.5 hours), and slowly eliminated (mean half-life was 25.9 hours) with a large volume of distribution (mean, 2,793 L). The area under the concentration-time curve increased linearly with dose. Using an E(max) model, neutropenia was shown to be proportional to exposure. CONCLUSIONS: PD 0332991 warrants phase II testing at 125 mg once daily, at which dose neutropenia was the sole significant toxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phase 1 studies of palbociclib were conducted in patients with advanced cancers that express RB, establishing recommended phase 2 doses of 125 mg daily for 3 weeks on/1 week off (3/1 schedule) or 200 mg daily for 2 weeks on/1 week off (2/1 schedule) (69, 70).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [70]
In the citing paper
“Dose-limiting toxicities were neutropenia and thrombocytopenia that precluded continuous dosing.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [70]
In the citing paper
“Other side effects were mild, including fatigue, diarrhea, anemia, and nausea, with overall good tolerability on both dosing schedules.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [70]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 5×
“PD 0332991, administered as a single agent has showed antiproliferative effects (selective G1 arrest) on Rb-positive cells in vitro and tumor growth inhibition in several types of Rb-positive human breast and colon tumor xenografts (11), where PD 0332991 activitywas associatedwith reduced Rbphosphorylation and decreas…”
BackgroundInfluentialA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154 · cited 1×
“CDK4has been reported in some40%of cases ofmelanoma (6), and CDK4/6 deregulation has been reported in liposarcoma, multiple myeloma, and mantle cell lymphoma”
BackgroundHarbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752 · cited 10×
“Median age (range), y 54 (22–77) Male/female (n) 20/21 ECOG performance status, n 0 21 1 19 2 0 Primary tumor type, n (%) Melanoma 6 (15) Breast 5 (12) Kidney 4 (10) Ovarian 4 (10) Liposarcoma 4 (10) Colon 3 (7) Other 15 (37) Prior therapy, n (%) Any 41 (100) Chemotherapy 34 (83) 1–2 regimens 21 (51) 3 regimens 12 (29…”
BackgroundInfluentialModel of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
Friberg, L. E., Henningsson, A., Maas, H., Nguyen, L., & Karlsson, M. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.140 · Cited by 534 · cited 1×
“A semimechanistic physiologic model has been developed to describe the neutropenic effects of cytotoxic agents such as docetaxel, etoposide, paclitaxel, and irinotecan (25).”
MethodMalumbres, M., & Barbacid, M. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.008 · Cited by 338 · cited 2×
“25 3 4 (4–4) 10 (63) 58 (51) 3 4 (2–7) 16 (32) 119 (32) 50 3 4 (4–4) 21 (3) 134 (5) 3 4 (2–7) 36 (16) 274 (15) 75 7 4 (4–10) 29 (24) 199 (20) 6 4 (4–9) 59 (24) 492 (27) 100 3 4 (4–4) 47 (11) 331 (17) 3 7 (4–10) 85 (11) 592 (NA) 125 22 7 (2–24) 52 (43) 299 (44) 13 4 (1–10) 86 (34) 724 (38) 150 3 4 (4–4) 91 (2) 641 (5)…”
BackgroundFunctions of cyclin D1 as an oncogene and regulation of cyclin D1 expression
Tashiro, E., Tsuchiya, A., & Imoto, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00449.x · Cited by 270 · cited 1×
“25 3 4 (4–4) 10 (63) 58 (51) 3 4 (2–7) 16 (32) 119 (32) 50 3 4 (4–4) 21 (3) 134 (5) 3 4 (2–7) 36 (16) 274 (15) 75 7 4 (4–10) 29 (24) 199 (20) 6 4 (4–9) 59 (24) 492 (27) 100 3 4 (4–4) 47 (11) 331 (17) 3 7 (4–10) 85 (11) 592 (NA) 125 22 7 (2–24) 52 (43) 299 (44) 13 4 (1–10) 86 (34) 724 (38) 150 3 4 (4–4) 91 (2) 641 (5)…”
Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260
Self-citation
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
“Severe neutropenia has been frequently reported in phase III studies with other CDK 4 and 6 inhibitors and was a dose-limiting toxicity leading to the definition of intermittent dosing schedules.(5,6,28,29) This has not been the case in MONARCH 2 and other studies of abemaciclib, in which severe neutropenia has been i…”
ResultTreating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Self-citation
Metadata
- Authors
- Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-01-15
- Volume
- 18
- Issue
- 2
- Pages
- 568-576
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2136158663
- Cited by
- 366
- References
- 27
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 11 · 2023: 20 · 2022: 14 · 2021: 23 · 2020: 22 · 2019: 30 · 2018: 27 · 2017: 51 · 2016: 35 · 2015: 43 · 2014: 33 · 2013: 24 · 2012: 7
- FWCI
- 17.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Abramson Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- palbociclib, CDK4/6 inhibitors, retinoblastoma protein, advanced solid tumors, dose-limiting toxicity, maximum tolerated dose, neutropenia, pharmacokinetics, pharmacokinetic-pharmacodynamic relationship, Emax model, oral anticancer drugs
- MeSH terms
- Administration, Oral, Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Neoplasms, Neutropenia, Piperazines, Pyridines, Treatment Outcome, Cyclin-Dependent Kinases, Area Under Curve, Maximum Tolerated Dose, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-0509
- The paper
- Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012). Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-0509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.